WO2004026102A3 - Treatment of schizophrenia - Google Patents

Treatment of schizophrenia Download PDF

Info

Publication number
WO2004026102A3
WO2004026102A3 PCT/US2003/029427 US0329427W WO2004026102A3 WO 2004026102 A3 WO2004026102 A3 WO 2004026102A3 US 0329427 W US0329427 W US 0329427W WO 2004026102 A3 WO2004026102 A3 WO 2004026102A3
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
patient
treatment
tnf
interferon
Prior art date
Application number
PCT/US2003/029427
Other languages
French (fr)
Other versions
WO2004026102A2 (en
Inventor
Boris Skurkovich
Simon Skurkovich
Original Assignee
Advanced Biotherapy Inc
Boris Skurkovich
Simon Skurkovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/422,119 external-priority patent/US20040052790A1/en
Application filed by Advanced Biotherapy Inc, Boris Skurkovich, Simon Skurkovich filed Critical Advanced Biotherapy Inc
Priority to AU2003272553A priority Critical patent/AU2003272553A1/en
Publication of WO2004026102A2 publication Critical patent/WO2004026102A2/en
Publication of WO2004026102A3 publication Critical patent/WO2004026102A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention includes methods of treating schizophrenia in a patient where the method includes administration of antibodies to TNF-alpha and interferon-gamma to the patient. The invention further includes methods of treating schizophrenia in a patient where the method comprises administration of an antibody to TNF-alpha or interferon-gamma.
PCT/US2003/029427 2002-09-18 2003-09-17 Treatment of schizophrenia WO2004026102A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003272553A AU2003272553A1 (en) 2002-09-18 2003-09-17 Treatment of schizophrenia

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US41192502P 2002-09-18 2002-09-18
US60/411,925 2002-09-18
US10/422,119 2003-04-24
US10/422,119 US20040052790A1 (en) 2002-09-18 2003-04-24 Treatment of schizophrenia
US10/603,231 2003-06-25
US10/603,507 2003-06-25
US10/603,231 US20040136988A1 (en) 2002-09-18 2003-06-25 Treatment of schizophrenia
US10/603,507 US20040052792A1 (en) 2002-09-18 2003-06-25 Treatment of schizophrenia

Publications (2)

Publication Number Publication Date
WO2004026102A2 WO2004026102A2 (en) 2004-04-01
WO2004026102A3 true WO2004026102A3 (en) 2004-10-14

Family

ID=32034409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/029427 WO2004026102A2 (en) 2002-09-18 2003-09-17 Treatment of schizophrenia

Country Status (2)

Country Link
AU (1) AU2003272553A1 (en)
WO (1) WO2004026102A2 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERBAGCI ET AL: "Serum IL-1.beta., sIL-2R, IL-6, IL-8 and TNF-.alpha. in schizophrenic patients, relation with symptomology and responsiveness to risperidone treatment", MEDIATORS OF INFLAMMATION, vol. 10, April 2001 (2001-04-01), pages 109 - 115, XP002979017 *
MOISES ET AL: "The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia", BMC PSYCHIATRY, vol. 2, no. 8, July 2002 (2002-07-01), pages 1 - 14, XP002978759 *

Also Published As

Publication number Publication date
WO2004026102A2 (en) 2004-04-01
AU2003272553A1 (en) 2004-04-08
AU2003272553A8 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2003300200A1 (en) Valve treatment catheter and methods
PL401886A1 (en) Neutralising, a high-affinity anti-TNF-alpha isolated human antibody, use of this antibody, crystal containing the anti-TNF-alpha human antibody and a preparation containing the crystal
AUPR638101A0 (en) Composition and method for treatment of disease
AU2002367397A1 (en) Method and apparatus for improved vascular related treatment
AU2003285874A1 (en) HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
IL160278A0 (en) System and method for face and body treatment
AU2003228481A1 (en) Groundwater treatment system and method
AU2002316732A1 (en) Method and apparatus for the treatment of urinary tract dysfunction
AU2003202196A1 (en) Devices and methods for heart valve treatment
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
AU2002356050A1 (en) Method and apparatus for treatment of patients
ATE359079T1 (en) METHOD FOR TREATING NAUSEA, VOMITING, REGAGING, OR ANY COMBINATION THEREOF
AU2002351378A1 (en) Method and apparatus for treatment of amblyopia
AU2003287909A1 (en) Electro-therapeutic device and method of electro-therapeutic treatment
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
AU2003263712A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2002350319A1 (en) Method and system for the treatment of wastewater
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
AU2002220257A1 (en) Methods of treatment involving human mda-7
AU2002316162A1 (en) Method of increasing anti-neugc antibody levels in blood
AU2003298033A1 (en) Method and system for registration and guidance of intravascular treatment
AU2002358010A1 (en) Method and device for integrated plasma-melt treatment of wastes
AU2000279747A1 (en) Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
WO2002070011A3 (en) Treatment of ppar mediated diseases
WO2004026102A3 (en) Treatment of schizophrenia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP